

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	
		Filing Date	
		First Named Inventor	David WALLACH
		Group Art Unit	1642
		Examiner Name	
Sheet 1	of 2	Attorney Docket Number	WALLACH=16A

10903 U.S. PTO  
09/824134

04/03/01

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.†	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code* (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Number			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number	Kind Code <sup>5</sup> (if known)				
RL ↓	AA	WO	96/12735	A1	Schievella	05-02-1996		
	AB	WO	96/30404	A1	Goeddell	10-03-1996		
	AC	WO	96/31603	A2	Dixit et al	10-10-1996		
	AD	WO	96/36730	A1	Leder et al	11-21-1996		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
RL	AE	BAKER et al, "Transducers of life and death: TNF receptor superfamily and associated proteins", <u>Oncogene</u> 12(1):1-9 91996)			
I	AF	BOLDIN et al, "A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain", <u>J Biol Chem</u> 270(14):7795-7798 (1995)			
I	AG	CHINNAIYAN et al, "FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiated apoptosis", <u>Cell</u> 81:505-512 (1995)			
↓	AH	CLEMENT et al, "Fas and Tumor Necrosis Factor Receptor Mediated Cell Death: Similarities and Distinctions", <u>J Exp Med</u> 180:557-567 (1994)			

Examiner Signature	M. T. DAUOS	Date Considered	02/28/04
-----------------------	-------------	--------------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

of 2

**Complete if Known**

Application Number

Filing Date

First Named Inventor

David WALLACH

Group Art Unit

1642

Examiner Name

Attorney Docket Number

WALLACH=16A

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
AL	AI	ITOH et al, "A novel protein domain required for apoptosis", <u>J Biol Chem</u> 268(15):10932-10937 (1993)	
	AJ	NAGATA et al, "Fas and Fas ligand: A death factor and its receptor", <u>Advances in Immunology</u> 57:129-144 (1994)	
	AK	SONG et al, "Aggregation of the Intracellular Domain of the Type 1 Tumor Necrosis Receptor Defined by the Two-hybrid System", <u>J Biol Chem</u> 269(36):22492-22495 (1994)	
	AL	GenBank Accession No. Q15121: "Astrocytic phosphoprotein", November 1, 1997	
	AM	GenBank Accession No. X86809: "H. sapiens mRNA for major astrocytic phosphoprotein PEA-15", July 23, 1996	
	AN	GenBank Accession No. P16157: "Ankyrin 1 (Erythrocyte Ankyrin)", April 1, 1990	
	AO	GenBank Accession No. P08138: "Low-affinity nerve growth factor receptor precursor (NGF receptor)", August 1, 1988	
	AP	GenBank Accession No. P19438: "Tumor necrosis factor receptor 1 precursor (Tumor-necrosis factor binding protein 1)", February 1, 1991	
	AQ	GenBank Accession No. NP_002459: "Myeloid differentiation primary response gene (88)", March 19, 1999	
	AR	GenBank Accession No. P22366: "Myeloid/differentiation primary response protein MYD88", August 1, 1991	
	AS	GenBank Accession No. P35445: "FASL Receptor precursor (apoptosis-mediating surface antigen FAS) (APO-1 Antigen) (CD95 Antigen)", May 1, 1992	
	AT	GenBank Accession No. P53355: "Death-associated protein kinase 1 (DAP kinase 1)", October 1, 1996	

Examiner  
Signature

M. T. DAVOS

Date  
Considered

02/28/04

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.